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Abstract
Background: Research into Alzheimer’s disease and other dementias increasingly involves large-scale data-sharing
initiatives. The development of novel digital tools and assessments is likely to increase the need for these. This
presents ethics and governance challenges to ensure the use of these data is able to maximise the benefit to
patients and the public.
Discussion: We consider the challenges associated with informed consent and governance in the context of
dementia research. We set out the potential of novel data governance approaches for the future of data sharing for
dementia.
Summary: The data trust model proposed in discussions of data governance may have potentially valuable
application for dementia research. Such inclusive approaches to trustworthy data governance should be considered
as data-sharing initiatives are established and develop.
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Background
Big data derived from clinical records and research stud-
ies or produced incidentally in everyday life represent an
opportunity for dementia research, diagnosis and care
[1, 2]. The application of machine learning and artificial
intelligence techniques to cognitive, behavioural or bio-
logical data may contribute to the detection of early cog-
nitive decline, improve our ability to model the course
of the condition and help identify individuals who may
be most suitable for clinical trials.
The scale and nature of data present both a chal-
lenge and an opportunity for the governance of data
for dementia research. Challenges include maintaining
the trust of members of the public and patients in the
collection and use of data, ensuring that informed
consent protects the interests of research participants
and considering how to enable individuals to contrib-
ute their clinical or other data to research, and vice
versa. There is also a continuing need to support re-
searchers and companies to engage with data sharing.
These challenges prompt consideration of how data
infrastructures can maximise the use of data while pro-
tecting the interests of data donors. The UK’s Chief Med-
ical Officer, for example, proposes the creation of ‘data
banks’ based on shared expectations and trust between
patients, the public, the health service and researchers in
the public and private sectors [3]. Here, we consider how
data governance arrangements can support ethical and
sustainable use of diverse data for research into dementia.
We argue that new governance approaches can improve
data access, maximising benefit, while operating in ac-
cordance with, and protecting, the interests and values of
those who donate it.
Discussion
Consent and changing data ecosystems
Until recently, data for dementia research have primarily
come from clinical records or research data. International
data initiatives such as the Dementias Platform UK or the
Global Alzheimer’s Association Interactive Network aim to
bring these data together and make them widely available.
There is also currently growing interest in the potential of
digital tools for dementia research, for example, through
the use of mobile devices to assess gait, sleep, cognition or
speech [2, 4]. While this may result in new forms of data, it
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involves an imbrication of commercial and public sector
research that can be challenging for public trust [5]. Such
corporate-clinical collaborations may raise concerns about
privacy and corporate use of health data, as in the col-
laboration between the Royal Free Hospital in London
and Google Deepmind [6, 7].
Questions of ethics and governance should be at the
heart of how data initiatives develop, to ensure that they
can prove their trustworthiness to those who donate and
collect data. However, the scope and scale of data for
research presents challenges to data governance and eth-
ics. First, it is important to understand whether and how
people have consented to the sharing and use of their
data. It is also increasingly difficult to ensure that in-
formed consent is meaningful when both future uses
and users of data are unpredictable. The value and limits
of broad consent, in which consent is provided at the
outset for a wide, but not unlimited range of uses, have
been the subject of long-standing debate [8].
Dementia research represents a distinctive context for
consent, as it may involve vulnerable individuals who may
at some point lack the capacity to consent even when
supported by family members, carers or researchers. Rec-
ommendations for consent processes for data sharing for
dementia research developed by Thorogood and colleagues
for the Global Alliance for Genomics and Health empha-
sise that consent must support decision-making by persons
with dementia, protect them from exploitation and pro-
mote the common good [9]. Thorogood et al. argue that
these goals are best achieved through broad consent that is
designed to endure beyond a loss of capacity and that is
combined with ongoing oversight.
Governing data
Mechanisms for oversight or governance have received little
attention among the dementia research community [10, 11].
Transparent, proportionate and adaptable oversight can
support the sharing and use of data by enabling data do-
nors—whether patients, researchers or companies—to trust
that uses and users of data align with their values and inter-
ests [12].
Innovation in data collection has been accompanied by
that in data governance. One model that may have poten-
tial in the context of dementia research is that of the data
trust [13, 14]. Data trusts have been identified as poten-
tially valuable for health research, and similar approaches
have previously been proposed for the governance of bior-
esources [15–17]. A trust is a legal way to manage rights
in an object for the benefit of another person. The essen-
tial characteristic of data trusts is that their structure, gov-
ernance and operating practices make sharing of data
possible in a fair, safe and equitable way [15].
A data trust would act as an independent and sustain-
able steward of data from diverse sources, rather than
adding governance to individual studies or being created
de novo alongside each data initiative. It could receive and
take responsibility for data from researchers, companies
or health systems. In the EU, the General Data Protection
Regulation further establishes a right to data access for
data subjects, and limited rights to portability, which may
enable individuals themselves to access and share data.
A trust with the goal of furthering understanding of age-
ing and dementia would be co-designed by and reflect the
values and preferences of all stakeholders, including
people with dementia, families and research participants
but also the wider public, charities, researchers and com-
panies. This process could build on existing engagement
activities with people with and without dementia, as well
as deliberative approaches similar to those previously
adopted to incorporate wider patient and community per-
spectives in the development of biobanks [18–20].
Once operational, the use and sharing of these data
would be managed by both expert and lay trustees in
line with the values established and codified through
these deliberations. A trust would commit to making
these data available and interoperable, contributing to
releasing data held in silos in the public and private sec-
tors. Finally, a trust would be able to exert effective
stewardship over data, denying or withdrawing access
where necessary.
Data trusts are an emerging concept and their imple-
mentation requires piloting and experimentation. Lessons
may be learned from the experience of bioresources; for
example, the Michigan BioTrust, which has fiduciary re-
sponsibility for a repository of neonatal dried blood spots,
aims to ensure that research is consistent with public and
private interests through a combination of a Community
Values Advisory Board alongside Scientific and Ethics
Advisory Boards [17]. A series of pilots in non-biomedical
domains for the UK Open Data Institute have also ex-
plored the potential of trust models. They suggest that for
stakeholders and the public to have trust in a data trust, it
has to be seen to reflect their issues, expectations and per-
spective on trade-offs; focus on building consensus; and
be open, honest and accountable [13].
As an independent, transparent body, incorporating
the interests and perspectives of multiple stakeholders, a
dementia data trust could provide an architecture for
‘trustworthy’ oversight by linking the long-term use of
data to a clear set of values, goals and principles. This
would support the validity of broad consent and enable
the protection of the interests of research participants/
data donors even in circumstances where they may no
longer have the capacity to provide informed consent.
Summary
Large-scale initiatives based on multimodal data from di-
verse sources are increasing central to dementia research.
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Facilitating effective and ethical use of data requires sys-
tematic attention to scalable and sustainable frameworks
for data governance. This includes prospectively consider-
ing the potential of different models to facilitate research
in the interests of stakeholders. A model that incorporates
features of an independent dementia data trust might pro-
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